Life sciences distribution is shifting toward AI-powered, resilient networks that improve speed, efficiency, compliance, and ...

After 30 years of use in transplant medicine, EBV-specific T cells offer key lessons for safer, scalable allogeneic cell therapies, writes Ivan Horak, M.D.

On this weeks episode of the Business of Biotech, Simeon George, M.D., Cofounder and CEO at SR One Capital Management, returns to the show to talk about how SR One evaluates biotech investment targets ...

On this weeks episode of the Business of Biotech, Cyriac Roeding talks about cofounding and leading Earli, a "bioAI" company using synthetic DNA switches and cancer-binding lipid nanoparticles to ...

I like building businesses. In the same way that you build a house, you start with a blueprint and the foundations … then you build around those, move the family in, and keep renovating and expanding ...

Why did John Oyler, an American entrepreneur, decide to build a global biopharmaceutical company with roots in China? Ask the chairman, cofounder, and CEO of BeiGene that question and you’re going to ...

In pharma, an oncology drug approval is a significant milestone. I have spent enough time in this space to know that it is also the moment where a different, less visible problem begins. The community ...

This month’s cover story delves into the background and business strategy of Krystal Biotech, a Pittsburgh-based developer of gene therapies for rare disease. Founded and led by Krish and Suma ...

A substantial share of biopharmaceutical drug launches (>50%) fail to meet their projected analyst forecasts (see also Simon-Kucher Biotech industry study 2019). With considerable investment going ...

Artificial intelligence (AI) is propelling the life sciences industry into a future filled with potential, where the rapid interpretation of complex biological data, the acceleration of drug discovery ...

Conferences and trade shows are great places to learn about your competitive environment, as most companies in the industry usually attend these events; this includes competitors, suppliers, customers ...

Patient safety is the top priority for regulators. While the industry and the public advocate for alternatives to animal testing, regulators require strong evidence that alternatives are equally safe ...